Wednesday, March 27, 2019

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Establishes Center of Excellence at Vogel Laboratory at NYU’s Center for Genomics and Systems Biology


Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables, and related services for the global life sciences and other industries worldwide, today announced the establishment of a Center of Excellence (“CoE”) at Dr. Christine Vogel’s laboratory at New York University’s Center for Genomics and Systems Biology. As a CoE, the lab will have free use of PBIO’s Barocycler 2320EXTREME (“2320EXT”) primary instrument system through the end of 2020. In addition, the collaboration will offer early access to new, modified, and/or improved versions of the 2320EXT instrument and its associated applications, as well as the opportunity to work closely with PBIO’s senior science and engineering staff on new developments in its pressure-based technology platforms. “We are pleased to have the opportunity to collaborate with Professor Christine Vogel, a well-respected thought leader in proteomics,” PBIO Chief Commercial Officer Dr. Bradford A. Young said in the news release. “We believe the 2320EXT has the potential to support and advance the exciting work that she and her team already have underway at the GSB Center. We further believe that the added exposure received by the PCT platform during the collaboration period will increase awareness of the benefits of our pressure-based technologies in helping to provide scientists with superior proteomic analyses. We believe this added awareness should result in increased products and services revenue in 2019 and beyond.”

To view the full press release, visit http://ibn.fm/eyAho

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html